// App-Quantinova.ai

POS1044 (2022) : GUSELKUMAB PROVIDES CONSISTENT AND DURABLE PAIN IMPROVEMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF 2 PHASE 3, RANDOMIZED, CONTROLLED CLINICAL TRIALS

Researchers

Presenter

  • P. Nash

Principal Investigators

  • L. S. Tam

  • W. C. Tsai

  • Y. Y. Leung

  • D. Furtner

  • S. Sheng

  • Y. Wang

  • M. Shawi

  • A. Kollmeier

  • J. Sherlock

  • D. Cua

Medical Centers

  • Griffiths University and University of Queensland, Department of Rheumatology Research, Maroochydore, Queensland, Australia

  • The Chinese University of Hong Kong, Department of Medicine & Therapeutics, Hong Kong, Hong Kong

  • Singapore General Hospital, Duke-NUS Medical School, Department of Rheumatology & Immunology, Singapore, Singapore

  • Janssen, a Division of Jonson & Johnson Pte Ltd., Singapore, Singapore

  • Janssen Research and Development, LLC, Department of Immunology, San Diego, CA, United States of America

  • Janssen Global Services, LLC, Department of Immunology, Raritan, NJ/Malvern, PA, United States of America

  • Janssen Research and Development, LLC, Department of Immunology, San Diego, CA, United States of America

  • Janssen Research and Development, LLC, Department of Immunology, San Diego, CA, United States of America

  • Kennedy Institute of Rheumatology, University of Oxford, Department of Rheumatology, Oxford, United Kingdom

  • Janssen Research and Development, LLC, Department of Immunology, San Diego, CA, United States of America

Locations

  • Australia

  • Hong Kong

  • Republic of South Korea

  • Singapore

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved